All News
Filter News
Found 2,621 articles
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
8/7/2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2023.
-
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
8/3/2023
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, reported business highlights and financial results for the second quarter ended June 30, 2023.
-
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
8/3/2023
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine.
-
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
8/3/2023
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the second quarter 2023.
-
The biopharma company reported sales of $2.24 billion in the second quarter for the cystic fibrosis treatment, beating analysts’ estimate, after it won FDA approval in children ages two to five in April.
-
Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets
8/1/2023
Solu Therapeutics today announced the closing of an oversubscribed $31 million seed financing co-led by Longwood and Santé Ventures, with additional participation from DCVC Bio, Astellas Venture Management, and Alexandria Venture Investments.
-
Vertex Reports Second Quarter 2023 Financial Results
8/1/2023
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the second quarter ended June 30, 2023 and updated its full year 2023 financial guidance.
-
Nexo Therapeutics Launches With $60 Million Series A Financing
7/26/2023
Nexo Therapeutics today emerged from stealth with a $60 million Series A financing.
-
The FDA’s CBER approved nine novel therapies in the first half of 2023, with several more high-profile decisions on deck for the second half of the year.
-
Former Bristol-Myers Squibb Head of Pharmacometrics Dr. Amit Roy Joins PumasAI to Support Drug Development Programs and DeepPumas Application
7/24/2023
PumasAI, a science-first organization that turns data into life-saving decisions faster, announced today that Dr. Amit Roy, former Executive Director and Head of Pharmacometrics at Bristol-Myers Squibb (BMS), has joined PumasAI as Distinguished Scientist.
-
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
7/17/2023
Lyndra Therapeutics today announced long-time Lyndra executive President and Chief Operations Officer Jessica Ballinger has been appointed President and CEO.
-
The FDA recently approved the first cellular therapy for Type 1 diabetes and others may not be far behind. But experts say challenges still exist to the widespread application of these treatments.
-
Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations
7/12/2023
Cryoport, Inc., a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, announced certain preliminary results for second quarter 2023 and updated its expectations for full year 2023 revenue expectations.
-
Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines
7/11/2023
Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors, announced the closing of a $150 million Series B financing.
-
Gene editing technologies are advancing rapidly in the clinic, with the potential first approval later this year, but challenges remain.
-
IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease
7/6/2023
IPS HEART today announced that the U.S. Food and Drug Administration (FDA) awarded a third Rare Pediatric Drug Designation (RPDD) for its product candidate, ISX9-CPC, for treatment of cardiomyopathy associated with Danon disease.
-
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
7/5/2023
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the appointment of Alyssa Levin as Chief Financial and Business Officer.
-
Vertex to Announce Second Quarter 2023 Financial Results on August 1
6/30/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on Tuesday, August 1, 2023 after the financial markets close.
-
Eli Lilly announced Thursday it will acquire former collaborative partner Sigilon Therapeutics to deepen its diabetic foothold with a potentially functional cure for Type 1.
-
Of the 30 patients given CellTrans’ Lantidra in two studies, 21 were insulin-free for at least a year and 10 were insulin-free for more than five years.